December 8, 2019
The Mackman lab studies the roles of tissue factor (TF), coagulation proteases and protease-activated receptors (PARs) in health and disease. We have established a variety of different disease models and have a larger number of transgenic mice deficient in different coagulation factors and PARs, as well as mice with low levels of TF and mice with cell type-specific knockout of TF, PAR1 and PAR2. We also use antibodies and pharmacological inhibitors of FXa and thrombin.
December 7, 2019
Dr. Moll is a clinician, clinical researcher and educator, with a particular focus on thrombosis and anticoagulation. His research interests include clinical trials on venous thromboembolism and better use of anticoagulants, antiphospholipid antibody syndrome, and postthrombotic syndrome.
December 7, 2019
As part of the Blood Research Center, we use our background in protein chemistry and enzyme kinetics to collaborate on studies looking at the molecular mechanisms that underlie both healthy hemostasis and the dysregulation of hemostasis seen in bleeding and thrombosis.
December 6, 2019
To date, my research interests have focused primarily on the investigation of the coagulation system in inflammatory disorders with a thrombotic phenotype. There is known to be a close interplay between inflammation and coagulation, however, not all inflammation predisposes to thrombosis. My work aims to help better understand the role and mechanism(s) of coagulation activation in certain inflammatory disorders, and how this coagulation activation may lead to both increased thrombotic risk as well as heightened inflammation through positive feedback mechanisms.
December 5, 2019
One area of interest is to investigate how the coagulation cascade contributes to the pathophysiology of neuroinflammation using mouse models of stroke and multiple sclerosis. We also study mechanisms of coagulation activation and clot formation in mouse models of sickle cell disease, and our goal is to identify the best mechanism of anti-coagulation to reduce the incidence of vaso-occlusive crisis, chronic inflammation, and end-organ damage associated with this blood disorder. The BRC enables us to interact with clinicians that are experts in sickle cell disease, which elevates the clinical relevance and impact of our research.
December 4, 2019
Dr. Reeves is a clinician-investigator and co-Principal Investigator of the 黑料网 Lineberger MDS Foundation Center of Excellence. Her clinical interests are focused in myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), and bone marrow failure syndromes.
December 3, 2019
The broad goal in my laboratory is to investigate crosstalk between coagulation and inflammation in animal models of disease. My primary interest is sickle cell disease, a blood disorder caused by a hemoglobin mutation that results in sickling of red blood cells.
December 1, 2019
Research in the Wolberg lab focuses on cellular, biochemical, and biophysical mechanisms that contribute to blood coagulation and disease, including arterial and venous thrombosis, pulmonary embolism, hemophilia, malignancy, and obesity.
August 8, 2017
Aberrant release of platelets into bone marrow of mice lacking Arp2/3 function in the megakaryocytic lineage. Whole-mount staining of femur bone marrow is shown. Green staining indicates platelets and megakaryocytes, red staining indicates endothelial cells, and blue staining indicates nuclei. See the article by Paul et al.